......

Associate Professor, Ph.D, MD Yi Hyeon Gyu

  4.7 out of 5   |  54 Patient Ratings
About

Prof. Yi Hyeon Gyu is Head of Oncology and Hematology Department CUM Head of Oncology and Hematology Clinic in Vinmec Times City International General Hospital. He is former Associate professor in Department of Hematology and Oncology, School of medicine, Inha University, South Korea. After moving to Vinmec Hospital, he have worked as Head of Oncology ward. He has much experienced in the fields of hematology, hematopoietic stem cell transplantation, and medical oncology in South Korea.     

He graduated from School of medicine, Inha University in 1999 and completed medical residency program in department of Internal medicine at Inha university Hospital in 2007. He defended his PhD. thesis in 2010 and was appointed as a Medical Professor in Hematology and Oncology in 2008. 

He is an expert of the diagnosis and treatment for hematological and oncologic diseases, cell therapy, and hematopoietic stem cell transplantation. He was active member in Korean academic societies of hematology and oncology. He worked in Inha university hospital in South Korea and played important role in hematopoietic stem cell transplantation clinic and department of hematology and oncology, and anti-smoke support center as vice-president. He also established and managed hospice-palliative center in Inha university hospital. He contributed to medical education in Inha university as vice-director of medical education center and head of department of student counseling. He was principal investigator and co-worker of many clinical trials and involved in Korean government training program for clinical trial staffs. He has published over 50 international journals in the field of hematology, oncology, cell therapy, hematopoietic stem cell transplantation and other molecular genetic research. He moved to Vinmec International Hospital at 2017 to enhance the advance of the field of hematology and oncology, and the establishment of VINUNI project.

  Overall
  4.7 out of 5

Clinical expertise

4.7

Communication

4.7

Professional appearance and courtesy

4.8
Roles

Head of Oncology and Hematology Department CUM Head of Oncology and Hematology Clinic

Experience
  • 2003 - 2006: Residentship, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
  • 2007 - 2008: Clinical instructor, Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
  • 2008 - 2011: Full time instructor, Division of Hematology and Oncology, Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea
  • 2011 - 2014: Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea
  • 2014 - 2017: Associate Professor, Division of Hematology and Oncology, Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea
  • 2017 - 2019: Department of Oncology, Vinmec Times City International Hospital, Hanoi, Vietnam
  • 2019 - Now: Unit of Hematology and Cell therapy, Vinmec Times City international hospital  
  • 2019 - Now: Head of Oncology and Hematology Department CUM Head of Oncology and Hematology Clinic, Vinmec Times City International hospital 
Awards and recognition
  • Travel award, ICBMT 2018
  • Travel award, ASBMT 2019
Books, articles, and research
  • 1: Jung KS, Kim YJ, Kim YK, Park SK, Kim HG, Kim SJ, Park J, Choi CW, Do YR, Kim I, Park S, Mun YC, Jeong SH, Kim MK, Yi HG, Chang MH, Kim SY, Lee JH, Jang JH. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Clin Lymphoma Myeloma Leuk. 2019 Jun 27. pii: S2152-2650(19)30234-4

    2: Choi JY, Yi HG, Park CS, Shin DW, Kang JH. Inhibition of oxaliplatin-induced neurotoxicity by silymarin through increased expression of brain-derived neurotrophic factor and inhibition of p38-MAPK, Molecular & Cellular Toxicology 2019 ;15(2), 145–152

    3: Lee GW, Park SW, Go SI, Kim HG, Kim MK, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Kim H, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Yi HG, Moon JH, Choi CW, Kim SH, Kim BS, Park MR, Shim H, Song MK, Kim Y, Kim K. The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Acta Haematol. 2018;140(3):146-156.

    4: Kim WH, Bae JN, Lim J, Lee MH, Hahm BJ, Yi HG. Relationship between physicians' perceived stigma toward depression and physician referral to psycho-oncology services on an oncology/hematology ward. Psychooncology. 2018 Mar;27(3):824-830.

    5: Kim MK, Kim K, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Kim YS, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Kim H, Yi HG, Moon JH, Choi CW, Kim SH, Joo YD, Kim HG, Kim BS, Park MR, Song MK, Kim SY. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16790. [Epub ahead of print] 

    6: Yoo SH, Koh Y, Kim DY, Lee JH, Lee JH, Lee KH, Yoon SS, Park S, Park SK, Hong DS, Yi HG, Kim CS, Jang JE, Cheong JW, Moon J, Min YH, Sohn SK, Kim I; Korean Society of Blood and Marrow Transplantation. Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. Ann Hematol. 2017 Apr;96(4):605-615.

    7: Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. Acta Haematol. 2017;137(2):76-85

    8: Choi WY, Kim JH, Choi SJ, Park J, Park YH, Lim JH, Lee MH, Kim CS, Yi HG. Peritoneal lymphomatosis confused with peritoneal carcinomatosis due to the previous history of gastric cancer: a case report. Clin Imaging. 2016 Sep-Oct;40(5):837-9. 

    9: Park YH, Lim JH, Yi HG, Lee MH, Kim CS. Factor V Deficiency in Korean Patients: Clinical and Laboratory Features, Treatment, and Outcome. J Korean Med Sci. 2016 Feb;31(2):208-13. 

    10: Yi HG, Yahng SA, Kim I, Lee JH, Min CK, Kim JH, Kim CS, Song SU. Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean J Physiol Pharmacol. 2016 Jan;20(1):63-7. 

    11: Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology.. Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study. Acta Haematol. 2016;135(3):162-71. 

    12: Suh YJ, Lee JE, Lee DH, Yi HG, Lee MH, Kim CS, Nah JW, Kim SK. Prevalence and Relationships of Iron Deficiency Anemia with Blood Cadmium and Vitamin D Levels in Korean Women. J Korean Med Sci. 2016 Jan;31(1):25-32. 

    13: Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study. Int J Hematol. 2016 Feb;103(2):180-8. 

    14: Jeong SH, Kim YJ, Lee JH, Kim YK, Kim SJ, Park SK, Do YR, Kim I, Mun YC, Kim HG, Lee WS, Yi HG, Joo YD, Choi CW, Kim SR, Na SM, Jang JH. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Oncotarget. 2015 Dec 29;6(42):44985-94. 

    15: Baek YS, Shin SH, Yi HG, Kim DH, Woo SI, Park KS, Kwan J. Cardiac involvement in CD56 negative primary pancreatic extranodal NK/T-cell lymphoma, nasal type, presenting with ventricular tachycardia during the early stages of chemotherapy. Intern Med. 2014;53(20):2333-6. 

    16: Lee HJ, Heo DS, Cho JY, Han SW, Chang HJ, Yi HG, Kim TE, Lee SH, Oh DY, Im SA, Jang IJ, Bang YJ. A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. Cancer Res Treat. 2014 Jul;46(3):234-42. 

    17: Yi HG, Lee MH, Kim CS, Hong J, Park J, Lee JH, Han BR, Kim HY, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology.. Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. Blood Res. 2014 Jun;49(2):95-9

    18: Moon Y, Jang WR, Yi HG, Park IS, Nahm CH, Choi JW, Kim JJ, Han SB. Klebsiella pneumoniae associated extreme plasmacytosis. Infect Chemother. 2013 Dec;45(4):435-40. 

    19: Joo HY, Chae MH, Lim JH, Yi HG, Lee MH, Kim CS, Park YH. A case of gastric cancer manifesting as a solitary brain metastasis in the cerebellopontine angle that mimicked acoustic neuroma. Chonnam Med J. 2013 Dec;49(3):133-5. 

    20: Yi HG, Kim JS, Suh C, Kim WS, Kwak JY, Lee JS, Kim YS, Joo YD, Min YH, Lee HG, Yoon SS, Won JH, Park S, Kim HC, Kim CS. Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. Blood Res. 2013 Jun;48(2):115-20. 

    21: Kim JS, Cheong JW, Kim YK, Park J, Mun YC, Kang HJ, Yi HG, Lee JH, Kim YS, Ryoo HM, Kim SH, Kim HY, Kim JY, Lee DG, Kim HG, Kim H, Joo YD, Min YH. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea. Ann Hematol. 2014 Jan;93(1):33-42

    22: Lee YG, Kim I, Yoon SS, Park S, Cheong JW, Min YH, Lee JO, Bang SM, Yi HG, Kim CS, Park Y, Kim BS, Mun YC, Seong CM, Park J, Lee JH, Kim SY, Lee HG, Kim YK, Kim HJ; Korean Society of Haematology AML/MDS working party.. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol. 2013 May;161(3):339-47. 

    23: Kim JC, Shin SH, Yi HG, Kim SH, Woo SI, Kim DH, Park KS, Kwan J. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib. Herz. 2013 Dec;38(8):931-3. 

    24: Yeo JY, Han JY, Lee JH, Park YH, Lim JH, Lee MH, Kim CS, Yi HG. A case of inguinal sparganosis mimicking myeloid sarcoma. Korean J Parasitol. 2012 Dec;50(4):353-5. 

    25: Lim JH, Lim JY, Kim YM, Kim CS, Choi SJ, Yi HG, Choi WG, Lee MH. Primary diffuse large B cell lymphoma of the base of tongue. J Cancer Res Ther. 2012 Jan-Mar;8(1):135-7. 

    26: Jung KH, Lim MJ, Kwon SR, Joo KW, Yi HG, Choi SJ, Park W. Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept. Mod Rheumatol. 2013 Jul;23(4):817-22. 

    27: Kim JW, Lee HJ, Yi HG, Kim BS, Bang SM, Kim JS, Kim I, Yoon SS, Lee JS, Kim CS, Park S, Kim BK. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol. 2012 May;87(5):479-83. 

    28: Yi HG, Piao CZ, Kim I, Kim HJ, Oh SY, Kim JW, Kim DY, Lim JH, Seo MD, Park E, Yoon SS, Kim BK, Kim CS, Park S. DAAM2 polymorphism is closely related to the clinical outcomes of allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Apr;91(4):571-6. 

    29: Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, Kim CS, Kim HJ, Lee JE. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J Thorac Oncol. 2011 Aug;6(8):1320-9. 

    30: Chang HJ, Lee MD, Yi HG, Lim JH, Lee MH, Shin JH, Choi SJ, Moon Y, Nahm CH, Kim CS. A case of blastic plasmacytoid dendritic cell neoplasm initially mimicking cutaneous lupus erythematosus. Cancer Res Treat. 2010 Dec;42(4):239-43. 

    31: Lim JH, Lee MH, Kim HG, Shin YW, Yi HG, Shin SH, Hur YS, Kim CS, Chang HJ. Three-weekly s-1 monotherapy as first-line treatment in elderly patients with recurrent or metastatic gastric cancer. Gut Liver. 2010 Dec;4(4):503-7. 

    32: Lee WS, Kim DH, Shin SH, Woo SI, Kwan J, Park KS, Park SD, Yi HG, Jeon SH. Complete atrioventricular block secondary to bortezomib use in multiple myeloma. Yonsei Med J. 2011 Jan;52(1):196-8. 

    33: Lim JH, Lee MH, Yi HG, Kim CS, Kim JH, Song SU. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases. Int J Hematol. 2010 Jul;92(1):204-7. 

    34: Lim JH, Lee MH, Lee MJ, Kim CS, Lee JS, Choi SJ, Yi HG. Plasmablastic lymphoma in the anal canal. Cancer Res Treat. 2009 Sep;41(3):182-5. 

    35: Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY, Bang YJ. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol. 2009 May;24(5):800-5. 

    36: Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW, Heo DS. Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Aug;65(2):242-6. 

    37: Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 2009 Jul;65(1):80-4. 

    38: Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Kim YJ, Lee SH, Kim DW, Yang SC, Kim YW, Heo DS. Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. Lung Cancer. 2008 Dec;62(3):381-4. 

    39: Lim KH, Kim S, Lee YS, Kim KH, Kim J, Rhee Jy, Kim HJ, Yi HG, Oh SY, Lim JH, Han SW, Lee S, Kim I, Yoon SS, Park S, Kim BK. Central pontine myelinolysis in a patient with acute lymphoblastic leukemia after hematopoietic stem cell transplantation: a case report. J Korean Med Sci. 2008 Apr;23(2):324-7. 

    40: Ryu SD, Kang JH, Yi HG, Nahm CH, Park CS. Hepatic flavin-containing monooxygenase activity attenuated by cGMP-independent nitric oxide-mediated mRNA destabilization. Biochem Biophys Res Commun. 2004 Nov 5;324(1):409-16. 

    41: Ryu SD, Yi HG, Cha YN, Kang JH, Kang JS, Jeon YC, Park HK, Yu TM, Lee JN, Park CS. Flavin-containing monooxygenase activity can be inhibited by nitric oxide-mediated S-nitrosylation. Life Sci. 2004 Oct 8;75(21):2559-72. 

    42: Park CS, Kang JH, Chung WG, Yi HG, Pie JE, Park DK, Hines RN, McCarver DG, Cha YN. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics. 2002 Jan;12(1):77-80. 

    43: Park CO, Yi HG. Apoptotic change and NOS activity in the experimental animal diffuse axonal injury model. Yonsei Med J. 2001 Oct;42(5):518-26. 

Services
  • Diagnosis and treatment of benign and malignant hematologic disease
  • Hematopoietic stem cell transplantation
  • Cell therapies including autologous immune enhancement therapy (AIET)
Education
  • 1992 - 1994: Inha University Premedical Course, Incheon, South Korea
  • 1994 - 1999: Inha University College of Medicine (M.D. License: 1999)
  • 1999 - 2001: Inha University Post graduate School (M.S. 2001, Pharmacology)
  • 2001 - 2010: Inha University Post graduate School (Ph.D. 2010, Pharmacology)
  • 2015 - 2017: Seoul Cyber University (B.D. 2017. Counseling Psychology)
Languages spoken
Patients ratings for Dr. Yi Hyeon Gyu:  54

The Patient Satisfaction Rating shown below is an average of all responses to the Doctor related questions in an Independent Customer Experience Survey conducted by Vinmec Helathcare System Quality Management department.

Responses are measured on a scale of 1 to 5 with 5 being the best score equivalent to "Excellent".

The comments are submitted by patients and reflect their views and opinions.

Overall
  4.7 out of 5

Clinical expertise

4.7

Communication

4.7

Professional appearance and courtesy

4.8
Ratings detail
5    
  36 ratings
4    
  17 ratings
3    
  1 ratings
2    
  0 ratings
1    
  0 ratings
 

There are no reviews for this doctor.

Chọn bác sĩ và giờ bạn muốn đặt khám từ lịch dưới đây. Để được tư vấn chọn bác sĩ, bạn có thể chat với chúng tôi trên trang web này hoặc gọi điện cho chúng tôi theo số trong Hotlines.